IP Library Granted Patent US 10,118,055
Granted Patent B2
US 10,118,055 · App. 13/155,965 · Granted Nov 6, 2018

Topical anti-pruritic compositions and methods of action of same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,118,055
App. No.
13/155,965
Granted
Nov 6, 2018
Kind
B2
Abstract

Topical anti-pruritic compositions and methods of using the same to treat pruritus. These anti-pruritic compositions are capable of temporarily or permanently reducing, inhibiting, treating, ameliorating, and/or preventing pruritic skin conditions, as well as other related skin conditions. In a particular aspect, the present formulations provide a quicker and more effective treatment of pruritus than do certain present pruritus-treating compositions.

Claims (17)

1. A method for treating pruritus in a patient comprising administering to a patient suffering from pruritus a first topical composition that is a lotion consisting essentially of pramoxine or a pharmaceutically acceptable salt thereof in an amount from about 0.1 to about 5% by weight,

at least one occlusive skin conditioning agent in an amount from about 1 to about 10% by weight,

an organosiloxane in an amount from about 0.5 to about 5% by weight,

an emulsifier in an amount from about 0.5 to about 10% by weight,

a gelling agent selected from the group consisting of gum arabic, gum tragacanth, locust beam gum, guar gum, xanthan gum, and carbomer, in an amount of about 0.1 to about 2% by weight,

an emollient in an amount of about 0.01 to about 5% by weight,

and an aqueous solvent in an amount from about 60 to about 90% by weight, wherein the administration of said first composition provides a more effective treatment of said pruritus in comparison to treatment of pruritus achieved by administration of a second topical composition comprising about 1% by weight hydrocortisone.

2. The method of claim 1 , wherein said occlusive skin conditioning agent is petrolatum.

3. The method of claim 1 , wherein said emollient has the following structural formula:

wherein R 1 can be a C 7 -C 20 straight or branched alkane, C 7 -C 20 straight or branched alkene, C 7 -C 20 straight or branched alkyne, C 7 -C 20 straight or branched alkanol, C 7 -C 20 straight or branched alkenol, C 7 -C 20 straight or branched alkynol, C 7 -C 20 straight or branched ester, and C 7 -C 20 straight or branched ether; and

wherein R 2 can be a C 1 -C 8 straight or branched alkane, C 1 -C 8 straight or branched alkanol, C 1 -C 8 straight or branched ether, C 3 -C 8 cyclic hydrocarbon optionally substituted with at least one R 3 , C 3 -C 8 aromatic hydrocarbon optionally substituted with at least one R 3 , and C 3 -C 8 aryl optionally substituted with at least one R 3 ;

wherein R 3 can be a C 1 -C 8 straight or branched alkane, C 1 -C 8 straight or branched alkene, C 1 -C 8 straight or branched alkyne, C 1 -C 8 straight or branched alkanol, C 1 -C 8 straight or branched alkenol, C 1 -C 8 straight or branched alkynol, C 1 -C 8 straight or branched ester, and C 1 -C 8 straight or branched ether.

4. The method of claim 1 , wherein said topical anti-pruritic composition begins reducing symptoms of pruritus exhibited by said patient within about 15 minutes.

5. The method of claim 4 , wherein said topical anti-pruritic composition begins reducing symptoms of pruritus exhibited by said patient within about 2 minutes.

6. The method of claim 1 , wherein said topical anti-pruritic composition alleviates said pruritus within about 4 hours.

7. The method of claim 6 , wherein said topical anti-pruritic composition alleviates said pruritus within about 1 hour.

8. The method of claim 3 , wherein said emollient is isopropyl myristate.

Assignments (6)
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; BELLUS MEDICAL, LLC; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0736 →
SECURITY INTEREST Recorded Dec 8, 2021
From: CROWN LABORATORES, INC.; BELLUS MEDICAL, LLC; STRIVECTIN OPERATING COMPANY, INC.; NIADYNE, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 058340/0600 →
PATENT SECURITY AGREEMENT Recorded Nov 17, 2021
From: CROWN LABORATORIES, INC.; NIADYNE, INC.; STRIVECTIN OPERATING COMPANY, INC.; BELLUS MEDICAL, LLC
To: HAYFIN SERVICES LLP
Reel/Frame 058175/0256 →
TERMINATION AND RELEASE OF AMENDED AND RESTATED PATENT SECURITY INTEREST Recorded Sep 20, 2021
From: HAYFIN SERVICES LLP
To: CROWN LABORATORIES, INC.
Reel/Frame 057549/0760 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2019
From: STIEFEL LABORATORIES INC.
To: CROWN LABORATORIES, INC.
Reel/Frame 047993/0666 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 26, 2018
From: CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP
Reel/Frame 047983/0560 →